Anti-Cisplatin modified DNA 抗体 [CP9/19] (ab103261)
Key features and details
- Rat monoclonal [CP9/19] to Cisplatin modified DNA
- Suitable for: ELISA
- Reacts with: Species independent
- Isotype: IgG2a
製品の概要
-
製品名
Anti-Cisplatin modified DNA antibody [CP9/19] -
製品の詳細
Rat monoclonal [CP9/19] to Cisplatin modified DNA -
由来種
Rat -
アプリケーション
適用あり: ELISAmore details -
種交差性
交差種: Species independent -
免疫原
Full length protein corresponding to Cisplatin modified DNA. Cisplatin Modified Native DNA.
-
ポジティブ・コントロール
- RNA/DNA.
-
特記事項
This antibody enables the quantification of cisplatin-induced adducts on DNA. It has also been recently used for isolation of DNA fragments carrying adducts to enhance the sensitivity of subsequent PCR-based analyses and is central to ongoing studies of variation in the nature of cisplatin adducts formed in different cell lines.
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
製品の特性
-
製品の状態
Liquid -
保存方法
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid repeated freeze / thaw cycles. -
バッファー
Preservative: 0.02% Sodium azide
Constituent: 99.98% PBS -
Concentration information loading...
-
精製度
Protein A/G purified -
一次抗体 備考
This antibody enables the quantification of cisplatin-induced adducts on DNA. It has also been recently used for isolation of DNA fragments carrying adducts to enhance the sensitivity of subsequent PCR-based analyses and is central to ongoing studies of variation in the nature of cisplatin adducts formed in different cell lines. -
ポリ/モノ
モノクローナル -
クローン名
CP9/19 -
ミエローマ
Y3/Ag1.2.3 -
アイソタイプ
IgG2a -
研究分野
関連製品
-
Compatible Secondaries
-
Conjugation kits
-
Isotype control
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab103261の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
アプリケーション | Abreviews | 特記事項 |
---|---|---|
ELISA | (1) |
Use at an assay dependent concentration.
|
特記事項 |
---|
ELISA
Use at an assay dependent concentration. |
プロトコール
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
データシートおよび資料
-
SDS download
-
Datasheet download
参考文献 (41)
ab103261 は 41 報の論文で使用されています。
- Winardi D et al. Novel Aurora A Kinase Inhibitor Fangchinoline Enhances Cisplatin-DNA Adducts and Cisplatin Therapeutic Efficacy in OVCAR-3 Ovarian Cancer Cells-Derived Xenograft Model. Int J Mol Sci 23:N/A (2022). PubMed: 35163790
- Tangeda V et al. Lon upregulation contributes to cisplatin resistance by triggering NCLX-mediated mitochondrial Ca2+ release in cancer cells. Cell Death Dis 13:241 (2022). PubMed: 35296653
- Jones TM et al. Targeted CUL4A inhibition synergizes with cisplatin to yield long-term survival in models of head and neck squamous cell carcinoma through a DDB2-mediated mechanism. Cell Death Dis 13:350 (2022). PubMed: 35428778
- Nicholson HA et al. Fibroblast growth factor signalling influences homologous recombination-mediated DNA damage repair to promote drug resistance in ovarian cancer. Br J Cancer 127:1340-1351 (2022). PubMed: 35778553
- Zhang Y et al. BTF3 confers oncogenic activity in prostate cancer through transcriptional upregulation of Replication Factor C. Cell Death Dis 12:12 (2021). PubMed: 33414468